Drug Information

Drug General Information
Drug ID
D0C8NG
Former ID
DIB007542
Drug Name
BI 655064
Drug Type
Antibody
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 1 [524565]
Company
Boehringer ingelheim pharmaceuticals
Target and Pathway
Target(s) Tumor necrosis factor ligand superfamily member 5 Target Info [549729]
KEGG Pathway Cytokine-cytokine receptor interaction
NF-kappa B signaling pathway
Cell adhesion molecules (CAMs)
T cell receptor signaling pathway
Intestinal immune network for IgA production
Malaria
Toxoplasmosis
Asthma
Autoimmune thyroid disease
Systemic lupus erythematosus
Allograft rejection
Primary immunodeficiency
Viral myocarditis
NetPath Pathway IL2 Signaling Pathway
TNFalpha Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database IL4-mediated signaling events
CD40/CD40L signaling
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Beta2 integrin cell surface interactions
Calcium signaling in the CD4+ TCR pathway
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
TNFR2 non-canonical NF-kB pathway
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
WikiPathways Inflammatory Response Pathway
Allograft Rejection
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
References
Ref 524565ClinicalTrials.gov (NCT02009761) Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).. U.S. National Institutes of Health.
Ref 549729FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GM-CSFR-Alpha, In the Phase IIB Earth Explorer 1 Study

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.